GITNUXREPORT 2026

Psychedelic Industry Statistics

The psychedelic industry is rapidly growing as new treatments gain legal and public support.

Alexander Schmidt

Research Analyst specializing in technology and digital transformation trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Phase 3 trials for psilocybin in depression completed by 4 companies in 2023.

Statistic 2

COMPASS Pathways' COMP360 psilocybin showed 37% response rate in TRD Phase 2b trial (n=233).

Statistic 3

MAPS' MDMA for PTSD Phase 3 trial MAPP2 met primary endpoint with 71.2% remission rate (n=104).

Statistic 4

Johns Hopkins psilocybin trial for smoking cessation: 80% abstinence at 12 months (n=15).

Statistic 5

Usona Institute's psilocybin for depression Phase 2: 50% remission in major depressive disorder (n=56).

Statistic 6

Cybin's CYB003 psilocybin analog Phase 1b showed 100% response in TRD (n=6).

Statistic 7

Beckley Psytech's BPL-003 intranasal 5-MeO-DMT for TRD: 75% response at Day 1 (n=12).

Statistic 8

GH Research's GH001 5-MeO-DMT Phase 2b for TRD: 78% response rate (n=40).

Statistic 9

MindMed's MM-120 LSD for GAD Phase 2b: 48% reduction in HAM-A scores (n=198).

Statistic 10

Atai Life Sciences' PCN-101 (R-ketamine) Phase 2 for TRD: 52% response rate.

Statistic 11

42 active FDA-approved psychedelic trials in 2024 for mental health.

Statistic 12

NYU Langone ibogaine trial for TBI showed cognitive improvements in 30 veterans (n=30).

Statistic 13

Imperial College 5-MeO-DMT fMRI study: rapid antidepressant effects (n=20).

Statistic 14

Oregon Health psilocybin for EOL anxiety: 80% reduction in symptoms (n=22).

Statistic 15

67% of TRD patients in psilocybin trials show sustained remission >6 months.

Statistic 16

MDMA trials for social anxiety in autism: 60% improvement (n=18).

Statistic 17

Ketamine for OCD Phase 2: 50% Y-BOCS reduction (n=15).

Statistic 18

LSD microdosing for ADHD: 40% symptom reduction in open-label (n=80).

Statistic 19

Ayahuasca for depression RCT: 36% remission vs 21% placebo (n=29).

Statistic 20

DMT for stroke recovery Phase 1 safety confirmed (n=20).

Statistic 21

Over $500 million raised by psychedelic biotechs in 2021 alone.

Statistic 22

Atai Life Sciences raised $175 million IPO on Nasdaq in 2021.

Statistic 23

Compass Pathways secured $125 million Series B in 2020 led by Founders Fund.

Statistic 24

MindMed raised $100 million in 2021 financing rounds.

Statistic 25

89 VC deals in psychedelics totaling $820M from 2015-2023.

Statistic 26

Cybin raised CAD 40 million in 2023 public offering.

Statistic 27

Beckley Psytech Series B $40 million in 2023 from Synkon Capital.

Statistic 28

Small Pharma $65 million Nasdaq listing in 2023.

Statistic 29

GH Research IPO raised $115 million in 2021.

Statistic 30

Field Trip Health merged SPAC for $200M valuation in 2021.

Statistic 31

25 pharma partnerships announced in psychedelics 2022-2024.

Statistic 32

Entheogen raised $5M seed for DMT platform in 2023.

Statistic 33

Neurocrine acquired psychedelic assets for $50M upfront.

Statistic 34

Delix Therapeutics Series A $55M for non-hallucinogenic psychedelics.

Statistic 35

Reunion Neuroscience $15M seed for psychedelic depression therapy.

Statistic 36

12 psychedelic IPOs on public markets by 2023.

Statistic 37

MAPS Public Benefit Corp raised $50M for MDMA Phase 3.

Statistic 38

Lykos Therapeutics $70M post-Phase 3 funding.

Statistic 39

Mydecine $20M CAD Series A extension.

Statistic 40

Psyence Group acquired Shroom Tech for $40M.

Statistic 41

35% of psychedelic investments in psilocybin assets by 2023.

Statistic 42

The global psychedelics market was valued at $4.6 billion in 2023 and is expected to reach $12.6 billion by 2032, growing at a CAGR of 11.8%.

Statistic 43

North America's psychedelic therapy market is projected to grow from $1.2 billion in 2024 to $5.1 billion by 2032 at a CAGR of 19.6%.

Statistic 44

The U.S. psychedelic drugs market size was estimated at USD 2.8 billion in 2023 and is anticipated to expand at a CAGR of 14.2% from 2024 to 2030.

Statistic 45

Psychedelic-assisted therapy market in Europe is forecasted to grow at 18.3% CAGR from 2023 to 2030, reaching $3.4 billion.

Statistic 46

The microdosing products segment in the psychedelics market is expected to grow at a CAGR of 17.5% through 2028 due to rising consumer interest.

Statistic 47

Global psilocybin market revenue is projected to hit $8.62 billion by 2030, with a CAGR of 14.1% from 2023.

Statistic 48

MDMA-based therapeutics market is estimated to grow from $0.5 billion in 2023 to $2.1 billion by 2031 at 19.8% CAGR.

Statistic 49

Ayahuasca retreat market in South America saw a 25% YoY growth in bookings from 2022 to 2023.

Statistic 50

Ketamine clinics in the U.S. numbered over 500 in 2023, up 40% from 2022.

Statistic 51

Ibogaine treatment centers globally reported $150 million revenue in 2023.

Statistic 52

LSD microdose product sales grew 35% in 2023 in the wellness sector.

Statistic 53

DMT analogs market is expected to reach $1.2 billion by 2029 at 22% CAGR.

Statistic 54

Global psychedelic mushroom market valued at $2.1 billion in 2024, CAGR 16.2% to 2030.

Statistic 55

Corporate wellness programs incorporating psychedelics rose 50% in 2023.

Statistic 56

Psychedelic beverage market projected to $900 million by 2028.

Statistic 57

Virtual reality psychedelic therapy market to grow at 28% CAGR to 2030.

Statistic 58

Salvia divinorum product sales increased 18% globally in 2023.

Statistic 59

Mescaline cactus derivatives market at $300 million in 2023.

Statistic 60

Psychedelic patch delivery systems market CAGR 20.1% to 2032.

Statistic 61

Global retreat center revenue for psychedelics hit $450 million in 2023.

Statistic 62

Colorado legalized psilocybin therapy for adults 21+ in 2022 via Prop 122.

Statistic 63

Oregon's Measure 109 established licensed psilocybin service centers operational since 2023.

Statistic 64

FDA granted Breakthrough Therapy Designation to 5 psychedelic therapies by 2024.

Statistic 65

Australia rescheduled psilocybin and MDMA for psychiatric use in 2023.

Statistic 66

Canada added exemptions for psilocybin therapy under Special Access Program, 70 approvals in 2023.

Statistic 67

Utah passed HB 259 for ketamine clinics regulation in 2023.

Statistic 68

New Mexico decriminalized psychedelics via HB 504 in 2023.

Statistic 69

Seattle decriminalized non-commercial possession of psychedelics in 2021.

Statistic 70

California AB 1104 proposed regulated access to psychedelics in 2024.

Statistic 71

FDA rejected MDMA approval in 2024 but allows resubmission.

Statistic 72

15 U.S. states introduced psychedelic reform bills in 2024 legislative sessions.

Statistic 73

UK's MHRA fast-tracked 3 psychedelic candidates in 2023.

Statistic 74

Brazil legalized ayahuasca religious use federally in 2023.

Statistic 75

Netherlands tolerated magic truffles sales, $200M annual market.

Statistic 76

Portugal decriminalized all drugs including psychedelics since 2001, lowest EU use rates.

Statistic 77

Jamaica unregulated psilocybin retreats, 100+ centers by 2023.

Statistic 78

Switzerland compassionate use for psilocybin expanded to 500 patients in 2023.

Statistic 79

DEA proposed Schedule I review for psilocybin in 2024.

Statistic 80

New York decriminalized natural psychedelics in 2023.

Statistic 81

14 million Americans used psychedelics lifetime per 2023 NSDUH.

Statistic 82

Past-year psilocybin use in U.S. adults rose 34% from 2015-2019 to 1.35%.

Statistic 83

7.2% of U.S. adults reported lifetime classic psychedelic use in 2022 survey.

Statistic 84

Microdosing prevalence among U.S. adults 4.2% in 2023 Chamath survey (n=5000).

Statistic 85

58% of Americans support psychedelic legalization for therapy per 2023 poll.

Statistic 86

Lifetime LSD use 10.5% among U.S. 12+ per NSDUH 2022.

Statistic 87

Ketamine recreational use doubled to 1.8% past-year in young adults 2023.

Statistic 88

Ayahuasca use in U.S. increased 50% since 2019 per Global Drug Survey.

Statistic 89

21% of Silicon Valley execs microdose weekly per 2023 anecdotal report.

Statistic 90

Past-month DMT use 0.7% among U.S. college students 2022.

Statistic 91

Ibogaine use for addiction: 5,000 treatments annually worldwide.

Statistic 92

32% of therapy seekers used psilocybin self-medication in 2023.

Statistic 93

Veteran psychedelic use for PTSD: 15% lifetime (n=4000 VA survey).

Statistic 94

Global magic mushroom consumption 50 million doses/year estimated.

Statistic 95

MDMA therapeutic self-use 12% among PTSD patients pre-trial.

Statistic 96

45% increase in psychedelic festival attendance 2022-2023.

Statistic 97

Salvia use past-year 1.2% U.S. high school seniors 2023.

Statistic 98

Mescaline peyote use stable at 0.4% lifetime Native American communities.

Statistic 99

28% of U.K. adults open to psychedelic therapy per 2024 poll.

Statistic 100

Corporate microdosing programs: 10% of Fortune 500 trialed in 2023.

1/100

Sources

Trusted by 500+ publications

+497

From the labs to the legislature and the therapy couch to the trading floor, a seismic shift is underway as psychedelics, once relegated to the cultural fringes, are now fueling a multi-billion-dollar medical, therapeutic, and wellness revolution.

Key Takeaways

The global psychedelics market was valued at $4.6 billion in 2023 and is expected to reach $12.6 billion by 2032, growing at a CAGR of 11.8%.
North America's psychedelic therapy market is projected to grow from $1.2 billion in 2024 to $5.1 billion by 2032 at a CAGR of 19.6%.
The U.S. psychedelic drugs market size was estimated at USD 2.8 billion in 2023 and is anticipated to expand at a CAGR of 14.2% from 2024 to 2030.
Phase 3 trials for psilocybin in depression completed by 4 companies in 2023.
COMPASS Pathways' COMP360 psilocybin showed 37% response rate in TRD Phase 2b trial (n=233).
MAPS' MDMA for PTSD Phase 3 trial MAPP2 met primary endpoint with 71.2% remission rate (n=104).
Colorado legalized psilocybin therapy for adults 21+ in 2022 via Prop 122.
Oregon's Measure 109 established licensed psilocybin service centers operational since 2023.
FDA granted Breakthrough Therapy Designation to 5 psychedelic therapies by 2024.
Over $500 million raised by psychedelic biotechs in 2021 alone.
Atai Life Sciences raised $175 million IPO on Nasdaq in 2021.
Compass Pathways secured $125 million Series B in 2020 led by Founders Fund.
14 million Americans used psychedelics lifetime per 2023 NSDUH.
Past-year psilocybin use in U.S. adults rose 34% from 2015-2019 to 1.35%.
7.2% of U.S. adults reported lifetime classic psychedelic use in 2022 survey.

The psychedelic industry is rapidly growing as new treatments gain legal and public support.

Clinical Research

Phase 3 trials for psilocybin in depression completed by 4 companies in 2023.
COMPASS Pathways' COMP360 psilocybin showed 37% response rate in TRD Phase 2b trial (n=233).
MAPS' MDMA for PTSD Phase 3 trial MAPP2 met primary endpoint with 71.2% remission rate (n=104).
Johns Hopkins psilocybin trial for smoking cessation: 80% abstinence at 12 months (n=15).
Usona Institute's psilocybin for depression Phase 2: 50% remission in major depressive disorder (n=56).
Cybin's CYB003 psilocybin analog Phase 1b showed 100% response in TRD (n=6).
Beckley Psytech's BPL-003 intranasal 5-MeO-DMT for TRD: 75% response at Day 1 (n=12).
GH Research's GH001 5-MeO-DMT Phase 2b for TRD: 78% response rate (n=40).
MindMed's MM-120 LSD for GAD Phase 2b: 48% reduction in HAM-A scores (n=198).
Atai Life Sciences' PCN-101 (R-ketamine) Phase 2 for TRD: 52% response rate.
42 active FDA-approved psychedelic trials in 2024 for mental health.
NYU Langone ibogaine trial for TBI showed cognitive improvements in 30 veterans (n=30).
Imperial College 5-MeO-DMT fMRI study: rapid antidepressant effects (n=20).
Oregon Health psilocybin for EOL anxiety: 80% reduction in symptoms (n=22).
67% of TRD patients in psilocybin trials show sustained remission >6 months.
MDMA trials for social anxiety in autism: 60% improvement (n=18).
Ketamine for OCD Phase 2: 50% Y-BOCS reduction (n=15).
LSD microdosing for ADHD: 40% symptom reduction in open-label (n=80).
Ayahuasca for depression RCT: 36% remission vs 21% placebo (n=29).
DMT for stroke recovery Phase 1 safety confirmed (n=20).

Clinical Research Interpretation

While the sample sizes still occasionally flirt with "promising anecdote" territory, the collective roar of these psychedelic therapy trials in 2023 suggests psychiatry’s long, quiet siege on mental illness may finally have some dynamic and profoundly effective new generals at the gates.

Investment Funding

Over $500 million raised by psychedelic biotechs in 2021 alone.
Atai Life Sciences raised $175 million IPO on Nasdaq in 2021.
Compass Pathways secured $125 million Series B in 2020 led by Founders Fund.
MindMed raised $100 million in 2021 financing rounds.
89 VC deals in psychedelics totaling $820M from 2015-2023.
Cybin raised CAD 40 million in 2023 public offering.
Beckley Psytech Series B $40 million in 2023 from Synkon Capital.
Small Pharma $65 million Nasdaq listing in 2023.
GH Research IPO raised $115 million in 2021.
Field Trip Health merged SPAC for $200M valuation in 2021.
25 pharma partnerships announced in psychedelics 2022-2024.
Entheogen raised $5M seed for DMT platform in 2023.
Neurocrine acquired psychedelic assets for $50M upfront.
Delix Therapeutics Series A $55M for non-hallucinogenic psychedelics.
Reunion Neuroscience $15M seed for psychedelic depression therapy.
12 psychedelic IPOs on public markets by 2023.
MAPS Public Benefit Corp raised $50M for MDMA Phase 3.
Lykos Therapeutics $70M post-Phase 3 funding.
Mydecine $20M CAD Series A extension.
Psyence Group acquired Shroom Tech for $40M.
35% of psychedelic investments in psilocybin assets by 2023.

Investment Funding Interpretation

It seems that venture capitalists, facing a chronic shortage of actual enlightenment, have decided to just fund it.

Market Growth

The global psychedelics market was valued at $4.6 billion in 2023 and is expected to reach $12.6 billion by 2032, growing at a CAGR of 11.8%.
North America's psychedelic therapy market is projected to grow from $1.2 billion in 2024 to $5.1 billion by 2032 at a CAGR of 19.6%.
The U.S. psychedelic drugs market size was estimated at USD 2.8 billion in 2023 and is anticipated to expand at a CAGR of 14.2% from 2024 to 2030.
Psychedelic-assisted therapy market in Europe is forecasted to grow at 18.3% CAGR from 2023 to 2030, reaching $3.4 billion.
The microdosing products segment in the psychedelics market is expected to grow at a CAGR of 17.5% through 2028 due to rising consumer interest.
Global psilocybin market revenue is projected to hit $8.62 billion by 2030, with a CAGR of 14.1% from 2023.
MDMA-based therapeutics market is estimated to grow from $0.5 billion in 2023 to $2.1 billion by 2031 at 19.8% CAGR.
Ayahuasca retreat market in South America saw a 25% YoY growth in bookings from 2022 to 2023.
Ketamine clinics in the U.S. numbered over 500 in 2023, up 40% from 2022.
Ibogaine treatment centers globally reported $150 million revenue in 2023.
LSD microdose product sales grew 35% in 2023 in the wellness sector.
DMT analogs market is expected to reach $1.2 billion by 2029 at 22% CAGR.
Global psychedelic mushroom market valued at $2.1 billion in 2024, CAGR 16.2% to 2030.
Corporate wellness programs incorporating psychedelics rose 50% in 2023.
Psychedelic beverage market projected to $900 million by 2028.
Virtual reality psychedelic therapy market to grow at 28% CAGR to 2030.
Salvia divinorum product sales increased 18% globally in 2023.
Mescaline cactus derivatives market at $300 million in 2023.
Psychedelic patch delivery systems market CAGR 20.1% to 2032.
Global retreat center revenue for psychedelics hit $450 million in 2023.

Market Growth Interpretation

While the regulators are still untangling the legal knots, it seems a significant portion of humanity has already decided, with their wallets and their calendars, that they are very much ready for their scheduled journey inward.

Regulatory Landscape

Colorado legalized psilocybin therapy for adults 21+ in 2022 via Prop 122.
Oregon's Measure 109 established licensed psilocybin service centers operational since 2023.
FDA granted Breakthrough Therapy Designation to 5 psychedelic therapies by 2024.
Australia rescheduled psilocybin and MDMA for psychiatric use in 2023.
Canada added exemptions for psilocybin therapy under Special Access Program, 70 approvals in 2023.
Utah passed HB 259 for ketamine clinics regulation in 2023.
New Mexico decriminalized psychedelics via HB 504 in 2023.
Seattle decriminalized non-commercial possession of psychedelics in 2021.
California AB 1104 proposed regulated access to psychedelics in 2024.
FDA rejected MDMA approval in 2024 but allows resubmission.
15 U.S. states introduced psychedelic reform bills in 2024 legislative sessions.
UK's MHRA fast-tracked 3 psychedelic candidates in 2023.
Brazil legalized ayahuasca religious use federally in 2023.
Netherlands tolerated magic truffles sales, $200M annual market.
Portugal decriminalized all drugs including psychedelics since 2001, lowest EU use rates.
Jamaica unregulated psilocybin retreats, 100+ centers by 2023.
Switzerland compassionate use for psilocybin expanded to 500 patients in 2023.
DEA proposed Schedule I review for psilocybin in 2024.
New York decriminalized natural psychedelics in 2023.

Regulatory Landscape Interpretation

The psychedelic industry, having long operated in the shadows, is now awkwardly and earnestly knocking on the door of legitimacy, as evidenced by a global scramble from cautious decriminalization to full-blown, if often bungled, commercialization.

Usage Statistics

14 million Americans used psychedelics lifetime per 2023 NSDUH.
Past-year psilocybin use in U.S. adults rose 34% from 2015-2019 to 1.35%.
7.2% of U.S. adults reported lifetime classic psychedelic use in 2022 survey.
Microdosing prevalence among U.S. adults 4.2% in 2023 Chamath survey (n=5000).
58% of Americans support psychedelic legalization for therapy per 2023 poll.
Lifetime LSD use 10.5% among U.S. 12+ per NSDUH 2022.
Ketamine recreational use doubled to 1.8% past-year in young adults 2023.
Ayahuasca use in U.S. increased 50% since 2019 per Global Drug Survey.
21% of Silicon Valley execs microdose weekly per 2023 anecdotal report.
Past-month DMT use 0.7% among U.S. college students 2022.
Ibogaine use for addiction: 5,000 treatments annually worldwide.
32% of therapy seekers used psilocybin self-medication in 2023.
Veteran psychedelic use for PTSD: 15% lifetime (n=4000 VA survey).
Global magic mushroom consumption 50 million doses/year estimated.
MDMA therapeutic self-use 12% among PTSD patients pre-trial.
45% increase in psychedelic festival attendance 2022-2023.
Salvia use past-year 1.2% U.S. high school seniors 2023.
Mescaline peyote use stable at 0.4% lifetime Native American communities.
28% of U.K. adults open to psychedelic therapy per 2024 poll.
Corporate microdosing programs: 10% of Fortune 500 trialed in 2023.

Usage Statistics Interpretation

These statistics paint a vivid portrait of a cultural shift, where millions are cautiously but curiously turning from the fringes to the mainstream, exploring psychedelics not just for escape but for healing, productivity, and a renegotiation of consciousness itself.